Condition: Precursor B-Cell Acute Lymphoblastic Leukemia · Sponsor: First Affiliated Hospital of Zhejiang University
Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation. In the past decade, with the application of molecular targeted drugs and immunotherapy, the survival of B-ALL patients has significantly improved. In this study，we propose a treatment approach that combines Blinatumomab and Reduced-dose Chemotherapy in B-ALL adults. Our study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.
This description comes directly from the study's public registry record.
Jie Jin, M.D. · +8657187236896 · jiej0503@163.com
Chenying Li, Ph.D. · +8657187236896 · lcy890823@126.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003 | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06742515